FDA Authorizes New COVID Vaccines with Restrictions on Eligibility
August 27th 2025FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.
Phase III NIMBLE Trial Demonstrates Cemdisiran Efficacy in Generalized Myasthenia Gravis
August 27th 2025The Phase III NIMBLE trial met its primary and key secondary endpoints, with cemdisiran monotherapy showing robust efficacy in generalized myasthenia gravis and the cemdi-poze combination achieving near-complete complement inhibition. Regeneron plans a 2026 US regulatory submission.
Beyond Prediction: An Evidence-Based Framework for Assessing Site Selection Decisions
August 27th 2025A new systems-based framework helps sponsors and CROs move beyond prediction to understand why site selection succeeds or fails, enabling targeted interventions that boost recruitment, data quality, and trial efficiency.
How Research Sites Balance Funding Cuts and Efficiency Pressures
August 26th 2025Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), and Kyle McAllister, co-founder, CEO, Trially, discuss how research sites are navigating political funding pressures, adapting to NIH budget constraints, and leveraging new cost-containment strategies to sustain clinical research.
ACT Brief Episode 6: Supreme Court Ruling, VK2735 Obesity Trial, and Padcev-Keytruda Survival Gains
August 25th 2025In this episode of the Applied Clinical Trials Brief, we recap our three most-viewed stories of the week—covering the Supreme Court’s decision to uphold NIH funding cuts tied to DEI, Phase II data showing oral VK2735 achieved over 12% weight loss, and Phase III results where Padcev plus Keytruda improved survival in muscle-invasive bladder cancer.
Supreme Court Upholds NIH Funding Cuts Affecting DEI in Clinical Research
August 22nd 2025The Supreme Court has ruled 5-4 to allow the Trump administration’s NIH funding cuts to continue, impacting more than 1,700 medical research grants in areas including heart disease, HIV/AIDS, Alzheimer’s disease, and mental health.
Building Partnerships to Better Serve Underrepresented Trial Communities
August 22nd 2025In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), explains why trial inclusivity requires shared responsibility across sponsors, CROs, sites, and advocacy groups.
NCX 470 Meets Phase III Goal in Glaucoma With Strong Intraocular Pressure Reductions
August 21st 2025The Denali trial confirmed non-inferiority of NCX 470 to latanoprost in lowering intraocular pressure, with consistent efficacy, favorable safety, and supportive results from the earlier Mont Blanc study.
How Flexible Site Models Can Cut Recruitment Costs and Timelines
August 21st 2025In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), highlights how listening to site insights and adopting flexible models such as temporary community-based clinics, can reduce patient travel burdens, improve enrollment efficiency, and stretch trial budgets further.
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 20th 2025In this episode of the Applied Clinical Trials Brief, we spotlight a recent video interview in which Jon Walsh, founder and chief scientific officer of Unlearn.AI, shared how digital twins can improve trial efficiency, enhance patient-centric designs, align with regulatory expectations, and accelerate access to new therapies.
Overcoming Budget Barriers to Patient-Centric Trial Models
Published: August 20th 2025 | Updated: August 20th 2025In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), outlines how rigid budgeting and limited sponsor-site dialog often block innovative patient-centric solutions, stressing the need for more collaborative approaches to enable community engagement and flexible trial delivery.
How In-Home and Community Strategies Boost Recruitment and Diversity
August 19th 2025In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), explains why site-enabled approaches such as in-home visits and community-based outreach should be offered from the start of a trial to reduce recruitment delays, support patient needs, and improve trial diversity.
Phase II Trial Launches to Evaluate Hepzato in Liver-Dominant Colorectal Cancer
August 19th 2025The first patient has been dosed in a global Phase II study assessing Hepzato in combination with trifluridine-tipiracil and bevacizumab for liver-dominant metastatic colorectal cancer, with primary results expected by mid-2028.
Oral GLP-1/GIP Dual Agonist VK2735 Achieves Up to 12% Weight Loss in Phase II VENTURE Trial
August 19th 2025The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety over 13 weeks.
The Reality of Operational Flexibility for Trial Sites
August 18th 2025In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), discusses the challenges of achieving true operational flexibility in clinical trials—highlighting how SOPs, staffing, and budget constraints often limit site adaptability and contribute to staff burnout.
FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan for EGFR-Mutated NSCLC
August 18th 2025The FDA has awarded Breakthrough Therapy Designation to izalontamab brengitecan, a potential first-in-class bispecific antibody-drug conjugate, for patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who progressed after EGFR TKI and platinum chemotherapy, based on data from multiple clinical trials.